|
|||||
|
|
Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity |
|
| Authors: | David M. Nanus David P. Kelsen Roberta Lipperman Mario Eisenberger |
| Affiliation: | (1) The Gastrointestinal Section, Solid Tumor Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY, USA;(2) Division of Medical Oncology, Department of Medicine, University of Maryland, University of Maryland Cancer Center, Baltimore, Maryland, USA;(3) 1275 York Avenue, 10021 New York, NY, USA |
| Abstract: | Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m2 daily × 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression. |
| Keywords: | ifosfamide phase II epidermoid carcinoma |
| 本文献已被 SpringerLink 等数据库收录！ | |